Intra-Cellular Therapies Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jul '25 Jul 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019
Market Capitalization	7,662	5,708	10,267	-	-	-	Upgrade
Market Cap Growth	-44.41%	-44.41%	-	-	-	-	Upgrade
Enterprise Value	6,456	4,458	8,661	-	-	-	Upgrade
Last Close Price	3.43	2.56	4.59	-	-	-	Upgrade
PE Ratio	29.30	22.39	49.42	-	-	-	Upgrade
Forward PE	17.84	7.83	17.10	-	-	-	Upgrade
PS Ratio	2.58	1.92	3.09	-	-	-	Upgrade
PB Ratio	5.98	4.46	7.35	-	-	-	Upgrade
P/TBV Ratio	6.00	4.47	7.35	-	-	-	Upgrade
P/FCF Ratio	26.41	19.67	17.53	-	-	-	Upgrade
P/OCF Ratio	24.74	18.43	15.85	-	-	-	Upgrade
PEG Ratio	-	0.29	-	-	-	-	Upgrade
EV/Sales Ratio	2.17	1.50	2.60	-	-	-	Upgrade
EV/EBITDA Ratio	20.56	17.23	33.58	-	-	-	Upgrade
EV/EBIT Ratio	27.66	19.10	40.42	-	-	-	Upgrade
EV/FCF Ratio	22.25	15.37	14.79	-	-	-	Upgrade
Debt / Equity Ratio	0.08	0.08	0.09	-1.09	-1.12	-1.02	Upgrade
Debt / EBITDA Ratio	0.31	0.31	0.40	38.99	-	-	Upgrade
Debt / FCF Ratio	0.33	0.33	0.22	-	-	20.70	Upgrade
Asset Turnover	1.40	1.40	1.61	1.49	1.95	2.12	Upgrade
Inventory Turnover	19.21	19.21	18.71	15.93	32.14	25.97	Upgrade
Quick Ratio	2.10	2.10	2.21	1.60	0.92	0.51	Upgrade
Current Ratio	2.34	2.34	2.34	1.78	1.02	0.61	Upgrade
Return on Equity (ROE)	19.39%	19.39%	-	-	-	-	Upgrade
Return on Assets (ROA)	6.86%	6.86%	6.47%	4.75%	-44.19%	-32.33%	Upgrade
Return on Capital (ROIC)	10.23%	10.23%	10.32%	9.30%	-143.76%	-177.59%	Upgrade
Return on Capital Employed (ROCE)	17.50%	17.50%	14.50%	15.80%	-	-	Upgrade
Earnings Yield	3.33%	4.47%	2.02%	-	-	-	Upgrade
FCF Yield	3.79%	5.08%	5.70%	-	-	-	Upgrade
Buyback Yield / Dilution	1.39%	1.39%	-205.57%	-	-	4.64%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.